Spyre Therapeutics, Inc. SYRE Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s current ratio?
- Spyre Therapeutics, Inc. (SYRE) reported current ratio of 9× in Q1 2026.
- How has Spyre Therapeutics, Inc.'s current ratio changed year-over-year?
- Spyre Therapeutics, Inc.'s current ratio increased by 11.3% year-over-year, from 8.1× to 9×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s current ratio?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s current ratio has grown at a 7.8% compound annual growth rate (CAGR), from 9.1× to 13.3×.
- What does current ratio mean?
- Whether the company has enough short-term assets to cover its short-term bills.
- How do you interpret current ratio?
- Above 1.0 means short-term assets cover short-term liabilities. Very high values can signal idle cash or bloated inventory/receivables rather than strength — there's a healthy middle, not 'more is better'.
- How does current ratio compare across companies?
- Comparable within an industry. Working-capital-light businesses can operate safely below 1.0 by collecting before they pay.